SCHEDULE: Nantahala Capital Reduces Aprea Therapeutics Stake Below 5%

Nantahala Capital Management and its principals have reduced their beneficial ownership in Aprea Therapeutics, Inc. to 4.50% as of December 31, 2025.

Summary

• Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a beneficial ownership of 411,520 shares of Aprea Therapeutics, Inc. common stock.
• This ownership represents 4.50% of the total class of securities outstanding.
• The reported shares include 205,760 shares that can be acquired within sixty days through the exercise of warrants.
• The reporting persons hold shared voting and dispositive power over all 411,520 shares.
• Nantahala Capital Management is classified as an investment adviser, while Messrs. Harkey and Mack are control persons.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development, as a reduction in stake by a notable institutional investor often suggests a less bullish outlook or a strategic divestment, even if not explicitly stated.

Negatives

• The reduction in beneficial ownership by Nantahala Capital Management and its principals to below the 5% reporting threshold could signal a decreased conviction in Aprea Therapeutics, Inc. or a strategic reallocation of capital.

Industry Context

StockSavvy.ai notes that institutional investors frequently adjust their positions in public companies based on evolving market conditions, company performance, or portfolio rebalancing strategies. A reduction below a key reporting threshold, such as 5%, often indicates a shift in investment thesis or a decision to reduce exposure, which can be a signal for other market participants.

Stakeholder Impact

• Shareholders may perceive the reduction in stake by a significant institutional investor as a negative indicator, potentially influencing market sentiment and trading decisions.
• The company's management might face questions regarding the reasons for the institutional investor's reduced position.

Key Dates

Recommendation

The reduction in a significant institutional stake, while not a direct reflection of the company's operational performance, introduces a degree of uncertainty. Investors should hold and monitor for further developments or fundamental company news rather than making immediate buy or sell decisions based solely on this ownership change.

Keywords

Aprea Therapeutics, Nantahala Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Warrants, Investment Adviser